Beliefs Associated with Pharmacy-Based Naloxone: a Qualitative Study of Pharmacy-Based Naloxone Purchasers and People at Risk for Opioid Overdose
- PMID: 30747371
- PMCID: PMC6565759
- DOI: 10.1007/s11524-019-00349-1
Beliefs Associated with Pharmacy-Based Naloxone: a Qualitative Study of Pharmacy-Based Naloxone Purchasers and People at Risk for Opioid Overdose
Abstract
Drug overdose is the leading cause of unintentional death in the USA and the majority of deaths involve an opioid. Pharmacies are playing an increasingly important role in getting naloxone-the antidote to an opioid overdose-into the community. The aim of the current study was to understand, from the perspective of those who had obtained naloxone at the pharmacy, whose drug using status and pain patient status was not known until the interviews were conducted, as well as those who had not obtained naloxone at the pharmacy but were at risk for overdose, factors that impact the likelihood of obtaining pharmacy-based naloxone (PBN). Fifty-two participants from two New England states were interviewed between August 2016 and April 2017. We used a phenomenological approach to investigate participants' beliefs about pharmacy-based naloxone. The social contextual model was chosen to structure the collection and analysis of the qualitative data as it takes into account individual, interpersonal, organizational (pharmacy), community, and societal influences on a specific health behavior. Of the 52 people interviewed, 24 participants had obtained naloxone from the pharmacy in the past year, of which 4% (n = 1) self-disclosed during the interview current illicit drug use and 29% (n = 7) mentioned using prescribed opioid pain medication. Of the 28 people who had not obtained naloxone from the pharmacy, 46% (n = 13) had obtained an over the counter syringe from a pharmacy in the past month and had used an opioid in the past month, and 54% (n = 15) had used a prescribed opioid pain medication in the past month but did not report a syringe purchase. Several main themes emerged from the interview data. Individual-level themes were as follows: helplessness and fear, naloxone as empowerment to help, and past experiences at the pharmacy. Interpersonal-level themes were as follows: concern for family and friends, and sources of harm reduction information. Themes associated with pharmacy-level influence were as follows: perceived stigma from pharmacists, confusion at the pharmacy counter, and receptivity to pharmacists' offer of naloxone; community-level themes were as follows: community caretaking and need for education and training. Finally, themes at the societal-level of influence were as follows: generational crisis, and frustration at lack of response to opioid crisis. Overall our findings reveal factors at multiple levels which may play a role in likelihood of obtaining naloxone at the pharmacy. These factors can be used to inform interventions seeking to increase provision of pharmacy-based naloxone.
Keywords: Interviews; Naloxone; Opioid; Overdose; Pharmacy; Qualitative; USA.
Similar articles
-
If we build it, will they come? Perspectives on pharmacy-based naloxone among family and friends of people who use opioids: a mixed methods study.BMC Public Health. 2022 Apr 13;22(1):735. doi: 10.1186/s12889-022-13078-z. BMC Public Health. 2022. PMID: 35418048 Free PMC article.
-
Pharmacy leaders' beliefs about how pharmacies can support a sustainable approach to providing naloxone to the community.Res Social Adm Pharm. 2020 Oct;16(10):1493-1497. doi: 10.1016/j.sapharm.2020.01.006. Epub 2020 Jan 18. Res Social Adm Pharm. 2020. PMID: 31983625
-
Why aren't Australian pharmacists supplying naloxone? Findings from a qualitative study.Int J Drug Policy. 2019 Jul;69:46-52. doi: 10.1016/j.drugpo.2019.03.020. Epub 2019 May 9. Int J Drug Policy. 2019. PMID: 31078908
-
What is known about community pharmacy supply of naloxone? A scoping review.Int J Drug Policy. 2016 Jun;32:24-33. doi: 10.1016/j.drugpo.2016.02.006. Epub 2016 Feb 15. Int J Drug Policy. 2016. PMID: 26949189 Review.
-
Pharmacists' naloxone services beyond community pharmacy settings: A systematic review.Res Social Adm Pharm. 2023 Feb;19(2):243-265. doi: 10.1016/j.sapharm.2022.09.002. Epub 2022 Sep 15. Res Social Adm Pharm. 2023. PMID: 36156267 Review.
Cited by
-
Pharmacy Naloxone Standing Order and Community Opioid Fatality Rates Over Time.JAMA Netw Open. 2024 Aug 1;7(8):e2427236. doi: 10.1001/jamanetworkopen.2024.27236. JAMA Netw Open. 2024. PMID: 39207758 Free PMC article.
-
Naloxone Availability and Cost After Transition to an Over-the-Counter Product.JAMA Health Forum. 2024 Jul 5;5(7):e241920. doi: 10.1001/jamahealthforum.2024.1920. JAMA Health Forum. 2024. PMID: 39058509 Free PMC article.
-
Naloxone Accessibility by Standing Order in North Carolina Community Pharmacies.J Am Pharm Assoc (2003). 2024 May-Jun;64(3):102021. doi: 10.1016/j.japh.2024.01.017. Epub 2024 Feb 1. J Am Pharm Assoc (2003). 2024. PMID: 38307248 Free PMC article.
-
Neighborhood and Individual Disparities in Community-Based Naloxone Access for Opioid Overdose Prevention.J Urban Health. 2024 Feb;101(1):64-74. doi: 10.1007/s11524-023-00821-z. Epub 2024 Jan 9. J Urban Health. 2024. PMID: 38196059
-
Naloxone analogy and opioid overdose terminology preferences among rural caregivers: Differences by race.J Am Pharm Assoc (2003). 2023 Sep-Oct;63(5):1521-1529.e3. doi: 10.1016/j.japh.2023.05.001. Epub 2023 May 4. J Am Pharm Assoc (2003). 2023. PMID: 37149142 Free PMC article.
References
-
- Understanding the epidemic | Drug overdose | CDC Injury Center. https://www.cdc.gov/drugoverdose/epidemic/index.html. Accessed 17 May 2018.
-
- Opioid overdose reversal with naloxone (Narcan, Evzio) | National Institute on Drug Abuse (NIDA). https://www.drugabuse.gov/related-topics/opioid-overdose-reversal-naloxo.... Accessed 17 May 2018.
-
- Walley AY, Xuan Z, Hackman HH, Quinn E, Doe-Simkins M, Sorensen-Alawad A, Ruiz S, Ozonoff A. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ. 2013;346:f174. doi: 10.1136/bmj.f174. - DOI - PMC - PubMed
-
- Ama A. Help save lives: co-prescribe naloxone to patients at risk of overdose. https://www.end-opioid-epidemic.org/wp-content/uploads/2017/08/AMA-Opioi.... Accessed 17 May 2018.
-
- General S. Surgeon General’s advisory on naloxone and opioid overdose. https://www.surgeongeneral.gov/priorities/opioid-overdose-prevention/nal.... Accessed 27 May 2018.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
